Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 3:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 112 matching trials from the live ClinicalTrials.gov search.
Conditions
Melanoma (Skin)
Interventions
polarized dendritic cells, non-polarized dendritic cells
Biological
Lead sponsor
Pawel Kalinski
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Conditions
Melanoma
Interventions
Mature dendritic cell (DC) vaccine, Cyclophosphamide 300mg/m^2, Pembrolizumab
Biological · Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Metastatic Melanoma
Interventions
TLPLDC Vaccine
Drug
Lead sponsor
Elios Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
7
States / cities
Birmingham, Alabama • Santa Monica, California • Miami Beach, Florida + 4 more
Conditions
Cancer of Prostate, Cancer of the Prostate, Neoplasms, Prostate, Neoplasms, Prostatic, Prostate Cancer, Prostate Neoplasms, Prostatic Cancer
Interventions
androgen ablation (AA), DC1 vaccine
Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
mDC3/8-KRAS Vaccine
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Brain Tumors
Interventions
DC/AAT, DC/AAT-Flu, DC/KLH
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
New York, New York
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Anti-HER2/HER3 Dendritic Cell Vaccine, Pembrolizumab
Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
3
States / cities
Tampa, Florida • Buffalo, New York • Charlottesville, Virginia
Conditions
Glioblastoma
Interventions
Human CMV pp65-LAMP mRNA-pulsed autologous DCs, Temozolomide, Varlilumab, Td, Unpulsed DCs
Biological · Drug
Lead sponsor
Annick Desjardins, MD
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Liver Cancer
Interventions
AFP
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
carcinoembryonic antigen RNA-pulsed DC cancer vaccine
Biological
Lead sponsor
Duke Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Renal Cell Carcinoma
Interventions
Electrofusion DC vaccine
Biological
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Terminated Phase 1 Interventional Results available

DC Vaccine in Colorectal Cancer

NCT03730948
Conditions
Colorectal Cancer
Interventions
DC vaccine
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Metastatic Colorectal Cancer
Interventions
DC-based vaccine
Biological
Lead sponsor
Pawel Kalinski
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cyclophosphamide, fludarabine phosphate, NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL, dendritic cell vaccine therapy, aldesleukin, fludeoxyglucose F 18, positron emission tomography, laboratory biomarker analysis
Drug · Biological · Radiation + 2 more
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
16 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Hodgkin Lymphoma, Non-Hodgkin Lymphoma
Interventions
LMP2A-loaded conventional DC vaccine, DUK-CPG-001
Biological
Lead sponsor
David Rizzieri, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Autologous Dendritic Cell-Adenovirus CCL21 Vaccine, Pembrolizumab
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Completed Phase 1Phase 2 Interventional Results available

Autologous Dendritic Cell Vaccine in HIV1 Infection

NCT00510497
Conditions
HIV Infections
Interventions
Autologous HIV-1 ApB DC Vaccine
Biological
Lead sponsor
Sharon Riddler
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Non-Small Cell Lung Cancer (NSCLC)
Interventions
autologous dendritic cell adenovirus CCL21 vaccine
Biological
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
West Los Angeles, California
Conditions
Type 1 Diabetes
Interventions
Diabetes-suppressive dendritic cell vaccine, control dendritic cells
Biological
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Metastatic Melanoma, Absence of CNS Metastases
Interventions
Proteasome siRNA and tumor antigen RNA-transfected dendritic cells
Biological
Lead sponsor
Scott Pruitt
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Small Cell Lung Cancer, Lung Cancer, Relapsed Small Cell Lung Cancer
Interventions
Nivolumab, Ipilimumab, Dendritic Cell based p53 Vaccine
Drug · Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Gliomas, Medulloblastoma, Neuroectodermal Tumors, Primitive
Interventions
Vaccine (autologous dendritic cells), Decitabine and Hiltonol
Biological · Drug
Lead sponsor
University of Louisville
Other
Eligibility
2 Years to 25 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Louisville, Kentucky
Conditions
Breast Cancer, DCIS
Interventions
HER-2 Pulsed Dendritic cell Vaccine
Biological
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Multiple Myeloma
Interventions
Nivolumab, DC/myeloma fusions/GM-CSF
Drug · Biological
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts